Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2018

Revenue From Contract With Customer [Abstract]

Disaggregated Revenues by Timing of Transfer of Goods or Services

The following table presents our revenues, disaggregated by timing of transfer of goods or services (in thousands):

	Three Months Ended June 30, 2018						Six Months Ended June 30, 2018
	Product Revenue, net		Collaboration and License Revenue		Total		Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	2,265	$	—	$	2,265	$	2,871	$	—	$	2,871
Transferred over time		—		1,746		1,746		—		7,784		7,784
Total	$	2,265	$	1,746	$	4,011	$	2,871	$	7,784	$	10,655

Schedule of Changes in Contract Assets and Liabilities

The following table presents changes in our contract assets and liabilities for the six months ended June 30, 2018 (in thousands):

	Balance at Beginning of Period		Addition		Deduction			Balance at End of Period
Contract assets:
Unbilled - collaboration and license revenue	$	6,694	$	5,439	$	(5,642	)	$	6,491
Total contract assets	$	6,694	$	5,439	$	(5,642	)	$	6,491
Contract liabilities:
Deferred revenue	$	7,623	$	6,857	$	(4,359	)	$	10,121
Total contract liabilities	$	7,623	$	6,857	$	(4,359	)	$	10,121

Significant changes in the contract liabilities balances during the periods are as follows (in thousands):

	Three Months Ended as of June 30, 2018		Six Months Ended as of June 30, 2018
Cumulative catch-up adjustment to revenue related to a change in an estimate of the transaction price	$	91	$	1,980
Revenue recognized according to the current period performance that was included in the contract liability at the beginning of the period		753		4,032

Estimated Revenue Expected to be Recognized in Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of June 30, 2018 (in thousands):

Collaborator	Transaction Price Allocated to the Remaining Performance Obligation as of June 30, 2018		Expected Year By Which Revenue Recognition Will Be Completed		Percentage of Revenue Recognized
BMS and Pfizer - 2014 agreement	$	156		2019		99	%
BMS and Pfizer - 2016 agreement		2,383		2021		81	%
Daiichi Sankyo - 2014 agreement		3,736		2020		89	%
Daiichi Sankyo - 2016 agreement		4,212		2023		69	%
Bayer and Janssen - 2014 agreement		245		2019		99	%
Bayer - 2016 agreement		3,762		2023		72	%
Total	$	14,494